KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Debt to Equity: 2018-2025

Historic Debt to Equity for Castle Biosciences (CSTL) over the last 4 years, with Sep 2025 value amounting to $0.02.

  • Castle Biosciences' Debt to Equity fell 5.24% to $0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year decrease of 5.24%. This contributed to the annual value of $0.02 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Debt to Equity is $0.02, which was down 2.41% from $0.02 recorded in Q2 2025.
  • Castle Biosciences' Debt to Equity's 5-year high stood at $0.05 during Q1 2022, with a 5-year trough of $0.02 in Q3 2025.
  • In the last 2 years, Castle Biosciences' Debt to Equity had a median value of $0.02 in 2024 and averaged $0.02.
  • Data for Castle Biosciences' Debt to Equity shows a maximum YoY fell of 8.30% (in 2025) over the last 5 years.
  • Over the past 3 years, Castle Biosciences' Debt to Equity (Quarterly) stood at $0.05 in 2022, then reached $0.02 in 2024, then fell by 5.24% to $0.02 in 2025.
  • Its Debt to Equity was $0.02 in Q3 2025, compared to $0.02 in Q2 2025 and $0.02 in Q1 2025.